Skip to content

News Category: Health & Medical

Alphyn Biologics Completes First Cohort of Phase2a Clinical Trial of Topical Therapeutic for Mild-to-Moderate Atopic Dermatitis

By asianet

Alphyn Biologics ( https://c212.net/c/link/?t=0&l=en&o=3709054-1&h=2795132862&u=https%3A%2F%2Falphynbiologics.com%2F&a=Alphyn+Biologics ), a clinical-stage dermatology company developing first-in-class multi-target therapeutics, announced today that it has completed the first cohort of its Phase2a clinical trial of AB-101a, a topical therapeutic candidate for mild-to-moderate atopic dermatitis (AD) in adults and children as young as 2 years old. The first cohort enrolled AD patients without … Continued

RedHill Accelerates Opaganib’s Nuclear Radiation Protection Program – Positive Data Published

By asianet

Strong preclinical data, recently published in the International Journal of Molecular Sciences, from eight U.S government-funded in-vivo opaganib studies, supports opaganib’s potential as a nuclear radiation injury therapeutic for homeland security material threat medical countermeasures (MCM) and for antitumor radiotherapy As an oral, small molecule pill that is highly stable with a more than five-year … Continued

SENTINEL DIAGNOSTICS LAUNCHES SENTINAT(R) 200, THE FULLY AUTOMATED SAMPLE TO RESULT SYSTEM FOR THE DIAGNOSIS OF VIRAL INFECTIONS

By asianet

Sentinel CH. SpA today announced the launch of SENTiNAT(R) 200, the fully automated sample to result system, and SENT-NAT(R) SN200 Real-Time PCR assays for the quantitative detection of 10 viruses. SENTiNAT(R) 200 and STAT-NAT(R) SN200 kits represent the ideal solution for mid to large throughput laboratories engaged in the diagnosis of viral infections. SENTiNAT(R) 200 … Continued

TauRx Announces Additional Investment of USD119 million following announcement of Phase 3 LUCIDITY Topline Results

By asianet

– Substantial investment of USD119 million achieved by TauRx through a warrants exercise triggered by the announcement of LUCIDITY results in October, supporting HMTM regulatory submissions in UK, US and Canada, and preparation for market availability – Shareholder commitment to TauRx represents a significant success story for UK-based life sciences research and development in areas … Continued

LOTUS REPORTS ITS BEST QUARTER EVER WITH THE BIGGEST LAUNCH IN ITS HISTORY

By asianet

Lotus Pharmaceutical (1795: TT), a multinational pharmaceutical company, today reported its financial results for the third quarter ended 30 September 2022. Third quarter financial highlights: – Third quarter 2022 is the best quarter ever in the Company’s history, majorly driven by the successful launch of Lenalidomide in the US – the biggest launch in Lotus … Continued

TES Pharma Congratulates Intercept Pharmaceuticals on their Presentation of Phase 1 INT-787 Data at the AASLD Meeting and the Initiation of the Phase 2a FRESH Study in Patients with Severe Alcohol-Associated Hepatitis

By asianet

INT-787 is a selective next generation FXR agonist invented by TES Pharma and licensed to Intercept Pharmaceuticals INT-787 has shown strong anti-fibrotic and anti-inflammatory effects in animal models TES Pharma is dedicated to the identification of novel therapeutic targets and the discovery and development of new molecules to efficiently address the needs of patients with … Continued

Novavax Phase 3 COVID-19 Omicron Trial Supports the Continued and Future Use of Novavax Prototype Vaccine as a Booster

By asianet

— The Novavax BA.1 vaccine candidate met its primary strain-change endpoint allowing for development of variant vaccines, if necessary — Novavax’ prototype vaccine induced broad immune response against original Wuhan, BA.1, and BA.5 strains — The trial showed no benefit for a bivalent vaccine utilizing Novavax’ recombinant protein/adjuvant technology Novavax, Inc. (Nasdaq: NVAX), a biotechnology … Continued

EIT Health’s Venture Centre of Excellence Names ProductLife Group as Privileged Partner for Regulatory & Compliance

By asianet

– The ambitious EU initiative has already secured 2 billion euros of co-investment capabilities and has supported 60 innovative Biotech, Medtech & digital health start-ups to get to market or expand into new territories. – EIT Health, co-operator of the Venture Centre of Excellence alongside the European Investment Fund (EIF), has named ProductLife Group the … Continued

OMRON Declares Its Commitment to Doubling Energy Productivity by 2040 to Achieve Carbon Neutrality, Becoming Japan’s First Manufacturing Company to Join EP100

By asianet

OMRON Corporation headquartered in Shimogyo-ku, Kyoto, became a member of The Climate Group’s “EP100” (*1) initiatives. OMRON is the first Japanese company in the manufacturing industry and the fourth Japanese company in general to join the EP100 initiative, which brings together over 120 energy smart businesses committed to measuring and reporting on energy efficiency improvements. … Continued